Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 6/20 | 0.64 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.61 |
| ▸ | GRIK1 | P39086 | 10/20 | 0.57 |
| ▸ | GRIK2 | Q13002 | 10/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15025485 | 1.00 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL15025556 | 1.00 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL12629349 | 1.00 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL12410338 | 1.00 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL13621431 | 1.00 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL12492350 | 1.00 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL12410315 | 1.00 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL3471272 | 1.00 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL13224535 | 0.86 | SLC1A1 (0.54) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL12900234 | 0.86 | SLC1A1 (0.54) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9375497-B2 | [F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamine, derivatives thereof and use thereof and processes for their preparation | PIRAMAL IMAGING SA (CH) | 2016-06-28 | — | — | US | disclosed |
| CN-101595083-B | [F-18]-labeled l-glutamic acid, [F-18]-labeled l-glutamine, derivatives thereof and use thereof and processes for their preparation | BAYER SCHERING PHARMA AG | 2014-12-10 | — | — | CN | disclosed |
| US-20140301948-A1 | [F-18]-LABELED L-GLUTAMIC ACID, [F-18]-LABELED L-GLUTAMINE, DERIVATIVES THEREOF AND USE THEREOF AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-09 | — | — | US | disclosed |
| US-20100217011-A1 | [F-18]-LABELED L-GLUTAMIC ACID, [F-18]-LABELED L-GLUTAMINE, DERIVATIVES THEREOF AND USE THEREOF AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-26 | — | — | US | disclosed |
| CN-101595083-A | The L-L-glutamic acid of [F-18]-mark, the L-glutaminate of [F-18]-mark, their derivative and application and preparation method | BAYER SCHERING PHARMA AG INST (DE) | 2009-12-02 | — | — | CN | disclosed |
| EP-1923382-A1 | [18F] labelled L-glutamic acid, [18F] labelled glutamine, their derivatives, their use and processes for their preparation | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-21 | — | — | EP | disclosed |
| EP-1923382-A1 | [18F] labelled L-glutamic acid, [18F] labelled glutamine, their derivatives, their use and processes for their preparation | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100217011-A1 | [F-18]-LABELED L-GLUTAMIC ACID, [F-18]-LABELED L-GLUTAMINE, DERIVATIVES THEREOF AND USE THEREOF AND PROCESSES FOR THEIR PREPARATION | GLUL, GFPT1, QPCT | SLC1A1 13/4885SLC1A2 6/4885SLC1A3 12/4885 |
| US-20140301948-A1 | [F-18]-LABELED L-GLUTAMIC ACID, [F-18]-LABELED L-GLUTAMINE, DERIVATIVES THEREOF AND USE THEREOF AND PROCESSES FOR THEIR PREPARATION | GLUL, GFPT1, QPCT | SLC1A1 13/4885SLC1A2 6/4885SLC1A3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.